A marginal significance was observed in between-group difference in the left hippocampal volume (42.4mm3, 95%CI: −0.1 to 84.8; p = 0.051) and in AD signature CT (0.02mm, 95% CI: 0.0–0.04; p = 0.088), suggesting higher annual rate of atrophy and thinning in the placebo group.
Meta-analyses showed that antibodiesimproved cognition on ADAS-Cog {SMD = −0.06 [95% CI (−0.10; −0.02), I2 = 0%]} and MMSE {SMD = 0.05 [95% CI (0.01; 0.09), I2 = 0%]}, and showed a trend towards improvement on the cognitive/functional measure CDR-SOB {SMD = −0.03 [95% CI (−0.07; 0.00), 12 = 11%]}.
Results: Verubecestat treatment was associated with a highly significant reduction in GM tissue density at week 13 and week 78 in both dose groups, compared to placebo.